Emicizumab: Review of the literature and critical appraisal

ConclusionThe principal advantage of emicizumab is subcutaneous administration and effectiveness irrespective of the presence of inhibitors. Emicizumab could conceivably represent a new epoch in the treatment of people with haemophilia A.

Source: Haemophilia - November 15, 2018 Category: Hematology Authors: E. Carlos Rodriguez ‐Merchan, Leonard A. Valentino Tags: REVIEW ARTICLE Source Type: research